News: Portfolio 2011

TetraLogic Closes $23 Million Second Tranche of Series C Financing

- Phase 1b/2a Five-Arm Combination Cancer Study Initiated for Novel Smac Mimetic TL32711 -

MALVERN, Pa., Jan. 5, 2011 – TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that is has closed the $23 million second tranche of a Series C financing completed in October 2010.

 

The company will use the funds to advance the clinical development of its lead Smac mimetic drug candidate, TL32711. TetraLogic recently completed dosing in the first cohort of a Phase 1b/2a five-arm combination clinical study. The Phase 1b portion of the study is an open-label, non-randomized, dose-escalation study investigating the safety and tolerability of TL32711 in combination with standard-of-care chemotherapies in patients with advanced or metastatic solid tumors. Chemotherapeutics in the five-arm Phase 1b study include